Phase 1 Randomized Trial Testing Safety and Immune Response of a Multivalent Neisseria Gonorrhoeae Vaccine in Healthy Adults
Led by LimmaTech Biologics AG · Updated on 2026-09-23
142
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and immune response of a new vaccine candidate called LTB-NG6, designed to prevent Neisseria gonorrhoeae infection. The study focuses on healthy adults aged 18 to 50 years and is a phase 1 trial to assess initial safety and immune reactions. Participants are randomly assigned to receive either one of five different doses of the vaccine or a placebo.
Participants will receive two doses of either the investigational vaccine at varying dose levels or a placebo consisting of sodium chloride 0.9%. The vaccine includes six different Neisseria gonorrhoeae antigens and is administered in a two-dose schedule. The study is conducted using a double-blind design, meaning neither participants nor researchers know who receives which treatment during the trial.
During the study, participants will be monitored for local and systemic adverse events for seven days after each injection and for any other events for 28 days post-injection. Unsolicited adverse events will be followed throughout the study, which lasts around 18 months on average. Immune responses will be measured by antibody levels 28 days after the second injection, with additional examinations of safety and lab tests at baseline and after each dose. Participants will also complete diary forms and attend follow-up visits and phone calls throughout the trial.
CONDITIONS
Brief Title
Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine
Research Team
S
Steffen Haffner, Dr.
C
Christian Reh, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Good and stable general health based on medical history, labs, and physical exam
Willing and able to comply with study requirements like diary completion and follow-up visits
Signed informed consent
Available for the full trial duration including follow-up visits and calls
Negative pregnancy test for women of childbearing potential and willingness to use effective contraception during the trial
You will not qualify if you...
Health conditions that may interfere with trial participation or increase risk of adverse events
Acute or active infections or fever at enrollment
History or current diagnosis of gonorrhea or positive test for Neisseria gonorrhoeae
History of Neisseria meningitidis infection
Previous vaccination with Bexsero or any meningococcal serogroup B vaccine
Clinically significant abnormal lab results at screening
Conditions contraindicating intramuscular vaccination or blood draws
Known or suspected immune system impairment
Positive tests for active hepatitis B, hepatitis C, or HIV infection
Recent vaccination within 14 days before enrollment
Body mass index less than 19 or greater than 35
Recent systemic corticosteroid use or immunosuppressive therapy
Known allergy to vaccine components or trial equipment
Participation in another vaccine trial during this study
History of chronic or progressive disease interfering with trial
Use of investigational or non-registered products within 3 months
Recent immunoglobulin or blood product administration
Recent blood donation of 500 mL or more
Planned elective surgery during the trial period
Pregnancy, lactation, or intention to become pregnant during the trial
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Vaccination
Duration - Several weeks between doses
Participants receive two doses of either the investigational LTB-NG6 vaccine at one of five dose levels or a placebo injection.
2 visits for vaccine administration
Follow-up and Monitoring
Duration - Up to 18 months
Participants are monitored for side effects, complete diary forms, undergo blood tests, and attend follow-up visits and phone calls over approximately 18 months.
Multiple follow-up visits and phone calls
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
6
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles.
Weiyan Zhu, Christopher E Thomas, Ching-Ju Chen...